Printed from Voxsanity (voxsanity.com.au) — NCT07170150 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are willing and able to complete all parts of the study — including MRI scans, genetic testing, and brain imaging or spinal fluid tests — for the full duration of the trial, either independently or with help from a study partner
People whose vision and hearing are good enough, in the study doctor's judgment, to complete memory and thinking tests (glasses and hearing aids are allowed)
People who have evidence of Alzheimer's disease confirmed by a brain amyloid PET scan, or by a spinal fluid test measuring certain proteins (if a PET scan is not available)
People diagnosed with probable Alzheimer's dementia or mild cognitive impairment (early memory and thinking problems) caused by Alzheimer's disease, at a clinical stage 3 or 4
People who score 22 or higher on a standard memory test called the MMSE, and who score 0.5 or 1.0 on a standard assessment of daily functioning called the CDR-GS
People who have had a gradual, progressive decline in memory or thinking, reported by themselves or someone who knows them well, over at least the past year before the screening visit
People who score 85 or lower on the delayed memory portion of a standard thinking and memory test called the RBANS
People who have an available "study partner" (a person who knows them well and can assist or provide information as defined by the trial protocol)
Who may not be able to join:
People who have any condition other than Alzheimer's disease that could affect memory or thinking
People with a history or current diagnosis of significant blood vessel or stroke-related brain disease
People with a history of severe brain injury that caused lasting nerve damage or permanent changes to brain structure
People with a history or current diagnosis of a significant growth or mass inside the skull
People whose MRI scan shows significant abnormalities in the brain, who cannot tolerate an MRI procedure, or for whom an MRI is medically unsafe
People with other medical conditions — such as heart, liver, or kidney problems — that are not stable or well-managed, or that the study doctor believes could affect the person's safety or interfere with study results
People with a history of cancer, unless the cancer is considered cured or is a type with very low risk of spreading or causing death
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Royal Prince Alfred Hospital, Camperdown, New South Wales
Southern Neurology, Kogarah, New South Wales
KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales
Flinders Medical Centre, Bedford Park, South Australia
Queen Elizabeth Hospital, Woodville, South Australia
Box Hill Hospital, Box Hill, Victoria
Austin Health, Heidelberg, Victoria
Alfred Hospital, Melbourne, Victoria
Alzheimer?s Research Australia, Nedlands, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07170150
Sponsor: Hoffmann-La Roche
Phase: Phase 3
Status: Recruiting
Condition: Alzheimer's Disease
Trial contact: 888-662-6728
More information: https://clinicaltrials.gov/study/NCT07170150
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are willing and able to complete all parts of the study — including MRI scans, genetic testing, and brain imaging or spinal fluid tests — for the full duration of the trial, either independently or with help from a study partner
People whose vision and hearing are good enough, in the study doctor's judgment, to complete memory and thinking tests (glasses and hearing aids are allowed)
People who have evidence of Alzheimer's disease confirmed by a brain amyloid PET scan, or by a spinal fluid test measuring certain proteins (if a PET scan is not available)
People diagnosed with probable Alzheimer's dementia or mild cognitive impairment (early memory and thinking problems) caused by Alzheimer's disease, at a clinical stage 3 or 4
People who score 22 or higher on a standard memory test called the MMSE, and who score 0.5 or 1.0 on a standard assessment of daily functioning called the CDR-GS
People who have had a gradual, progressive decline in memory or thinking, reported by themselves or someone who knows them well, over at least the past year before the screening visit
People who score 85 or lower on the delayed memory portion of a standard thinking and memory test called the RBANS
People who have an available "study partner" (a person who knows them well and can assist or provide information as defined by the trial protocol)
Who may not be able to join:
People who have any condition other than Alzheimer's disease that could affect memory or thinking
People with a history or current diagnosis of significant blood vessel or stroke-related brain disease
People with a history of severe brain injury that caused lasting nerve damage or permanent changes to brain structure
People with a history or current diagnosis of a significant growth or mass inside the skull
People whose MRI scan shows significant abnormalities in the brain, who cannot tolerate an MRI procedure, or for whom an MRI is medically unsafe
People with other medical conditions — such as heart, liver, or kidney problems — that are not stable or well-managed, or that the study doctor believes could affect the person's safety or interfere with study results
People with a history of cancer, unless the cancer is considered cured or is a type with very low risk of spreading or causing death
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇵🇱 Poland
🇰🇷 South Korea
🇪🇸 Spain
🇨🇭 Switzerland
🇬🇧 United Kingdom
🇺🇸 United States
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.